Supplementary Materialsijms-19-03717-s001. of fibrotic lesions, including alveolar structural harm, alveolar interstitial thickening and silica-induced nodule development. The down-regulation of miR-542-5p was also seen in mouse fibroblast (NIH-3T3) treated with changing growth aspect 1 (TGF-1). The proliferation and migration ability of NIH-3T3 cells were inhibited with the transfection of miR-542-5p imitate also. Integrin 6 (Itga6), reported being a cell surface area protein connected with fibroblast proliferation, was verified to be always a immediate focus on of miR-542-5p. The knockdown of Itga6 inhibited the SU 5416 irreversible inhibition phosphorylation of FAK/PI3K/AKT significantly. To conclude, miR-542-5p includes a potential function for reducing the proliferation of fibroblasts and inhibiting silica-induced pulmonary fibrosis, that will be noticed by directly binding to Itga6 partially. Our data suggested that miR-542-5p might be a new therapeutic target for silicosis or other pulmonary fibrosis. = 8 per group). (B) The hematoxylin and eosin staining of lung sections (from mice received silica treatment for 0, 7, 14, 28, 56 days) reflected the distribution and severity degree of silicosis and the most representative results were shown. (C) Proteins of lung tissues from three randomly selected mice in Rabbit polyclonal to annexinA5 each group were extracted and Western blot was performed to detect the fibrosis markers (fibronectin, collagen I, -SMA and vimentin). Fn: fibronectin; Col(I): collagen I; Vim: vimentin. ImageJ software was used to perform a grayscale scan, with semi-quantitating protein bands. GAPDH was used as the interval reference. (D) Total RNA of lung tissues (from mice received silica treatment for 0, 7, 14, 28, 56 days) were extracted and the expression level of miR-542-5p was examined by qRT-PCR. U6 was used as the interval reference. Above all, * 0.05 versus the control group. 2.2. miR-542-5p Attenuates Silica-Induced Pulmonary Fibrosis In Vivo Given that miR-542-5p expression was reduced in fibrotic mouse lung tissues, we next assessed whether increased miR-542-5p was sufficient to prevent the progression of silica-induced fibrosis. To confirm this assumption, an intervention model of miR-542-5p was established in C57BL/6 mice. We co-injected a miR-542-5p agomir or miR-negative control (NC) on day 0 with silica via tracheal instillation and then injected miR-542-5p agomirs or miR-NC via the tail vein on day 7, day 14 and day 21 (Physique 2A). qRT-PCR SU 5416 irreversible inhibition analysis revealed that, after 28 days of treatment, the miR-542-5p agomir significantly restored the level of miR-542-5p SU 5416 irreversible inhibition reduced by silica (Physique 2B). In keeping with the pathological adjustments in Body 1B, silica treatment resulted in an average inflammatory SU 5416 irreversible inhibition response also, nodule collagen and formation deposition inside our prevention model. Nevertheless, the mice co-injected with miR-542-5p agomir and silica demonstrated attenuated fibrotic pathological manifestations set alongside the mice in the silica group (Body 2C, Supplementary document 1, Body S4). Furthermore, the up-regulation of miR-542-5p decreased the appearance degree of fibronectin also, collagen I, vimentin and -SMA (Body 2D). We scored for pulmonary fibrotic lesions then. The severity amount of fibrosis was decreased after miR-542-5p agomir administration in silica + the miR-542-5p agomir group, set alongside the silica group, while no significant transformation was seen in the amount of distribution (Desk 1). Open up in another window Body 2 Ectopically portrayed miR-542-5p acquired a therapeutic influence on silica-induced pulmonary fibrosis in mice. (A) The mouse style of miR-542-5p overexpression in silica-induced mouse pulmonary fibrosis. The C57BL/6 mice had been co-transfected with 200 nmol/kg of either miR-542-5p or miR-NC agomir with 50 mg/kg silica suspension system via intratracheal instillation and injected with 120 nmol/kg miR-542-5p or miR-NC agomir every week via the tail vein over another three weeks. Lung tissue had been harvested on time 28 (= 8 for every group). (B) The appearance degree of miR-542-5p was elevated in the lung tissue treated with miR-542-5p agomir, weighed against the mixed group treated using the miR-NC agomir. * 0.05 versus the SiO2 + agomir NC group. (C) Areas stained with hematoxylin and eosin of the group treated with silica + miR-542-5p agomir demonstrated a lighter amount of fibrosis weighed against the group treated with silica or silica + miR-NC agomir; one of the most consultant results had been shown right here. (D) Protein degrees of the fibrosis markers (fibronectin, collagen I, -SMA and vimentin) from the silica + miR-542-5p agomir group had been significantly reversed weighed against the silica + miR-NC agomir group (arbitrarily = 3 per group). The.